EDCTP neglected infectious disease priorities published

TDR news item
31 January 2014

The report of recommendations for 2014 priorities on neglected infectious diseases for the European and Developing Countries Clinical Trials Partnership (EDCTP) has been published. The core recommendations, which were developed at a June, 2013 stakeholder meeting, are summarized into the themes of vaccines, diagnostics and biomarkers, drugs, and capacity building.

This is the first time EDCTP is addressing neglected tropical disease research priorities and is part of an expansion of support. Its original mandate was to focus on HIV/AIDS, tuberculosis and malaria. This second programme beginning in 2014 not only extends into neglected infectious diseases, but also features larger and more costly phase III clinical trials, phase IV trials and more projects conducted jointly with partners.

TDR Director John Reeder was one of the 54 participants at the June 2013 meeting. He spoke in a panel on partnerships and collaborations, saying, “It is important to build an evidence base for new interventions, and African countries should be supported to generate this evidence themselves.” He also talked about the need to predict change and address questions such as, “Will the treatment continue to work? When can mass drug administration be stopped?”

TDR is partnering with EDCTP on research capacity building, specific research support, and coordination with the ESSENCE health research group of funders. The goal is to accelerate the speed at which either organization can do the work alone.

EDCTP is a partnership between 16 European countries, the European Union and sub-Saharan African countries. The original aim of the programme set up in 2003 was to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria.

For more information, contact:

Garry Aslanyan (aslanyang@who.int)